← Eichor
Study identifier: NCT06632444 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Condition: Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis  ·  Sponsor: Boehringer Ingelheim

PhasePhase 3
Planned participants1800
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function. This study has 2 parts. The purpose of the first part of this study is to find out the effect of survodutide on MASH and liver fibrosis. The purpose of the second part is to find out how safe and effective survodutide is in improving liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. The survodutide doses are slowly increased until the target dose is reached. All participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for up to 7 years. During this time, they regularly visit the study site or have remote visits by video call. For a…

This description comes directly from the study's public registry record.

Talk to the study team

Boehringer Ingelheim  ·  1-800-243-0127  ·  clintriage.rdg@boehringer-ingelheim.com

Always discuss trial participation with your own doctor first.

Locations (525)

University of Alabama at BirminghamBirmingham, Alabama, United StatesNot Yet Recruiting
The Institute for Liver Health II DBA Arizona Clinical TrialsPeoria, Arizona, United StatesRecruiting
Scottsdale Medical Specialists, LtdScottsdale, Arizona, United StatesRecruiting
Adobe Clinical Research, LLCTucson, Arizona, United StatesRecruiting
Arizona Liver Health - TucsonTucson, Arizona, United StatesRecruiting
Del Sol Research Management, LLCTucson, Arizona, United StatesRecruiting
Hope Clinical ResearchCanoga Park, California, United StatesRecruiting
Velocity Clinical Research-Chula VistaChula Vista, California, United StatesRecruiting
Southern California Research CenterCoronado, California, United StatesRecruiting
ARK Clinical ResearchFountain Valley, California, United StatesRecruiting
Fresno Clinical Research CenterFresno, California, United StatesRecruiting
Velocity Clinical Research-Gardena-69773Gardena, California, United StatesRecruiting

+ 513 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06632444